Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Always Have a Backup Plan to Be Active
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Javed Butler on Heart Failure and Diabetes
HOMERUN SLIDES — Great Clinical Presentation Highlights
CGM Review of Clinical Outcomes Studies Part 3
CLINICAL GEMS — The Best from Diabetes Texts
MOST POPULAR ARTICLES OF THE MONTH
#1 What Not to Trust
#2 Possible Breakthrough In Treating Type 2 Diabetes and Prediabetes
#3 WHO Guidelines Recommend Treatment Intensifications in Type 2 Diabetes
Editor's Note
Over the past couple of weeks, we have been sharing a slide series on the use of CGM and the value for our patients. This has been one of our most viewed slide series and indicates to us that you want to offer your patients the best technology for managing their diabetes.
Usually this means a pump used with a CGM device. This works well for patients who can afford both devices and hopefully will not have their supplies taken off their formularies for care. In addition, we know that the cost to use a CGM is much less than a pump, both in initial cost and monthly supply cost. The question is, if your patient can only afford one device and supplies for it, which should we choose?
This week, in our Homerun Slides, we look at the value of using a CGM device with multidose injections and if that is a viable choice for many of our patients.
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
A 60-year-old woman with type 2 diabetes and no serious health complications began an exercise program as part of a research study. It involved doing an hour of moderate aerobic exercise three days per week in a supervised setting (at a local Y). She showed up to all the training sessions, stating about a month into the 12-week training program that she was so happy to be active again, that she felt so much better physically and mentally and felt like she had “found herself” again.
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Javed Butler, MD, MPH, MBA, is the Patrick A. Lehan Professor and Chairman of the Department of Medicine Department at University of Mississippi. He is also Professor of Physiology and Biophysics. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the Director for heart failure research at Emory University and Director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, looking at multiple daily injections while using CGM.
CLINICAL GEMS — The Best from Diabetes Texts
This chapter will concentrate on the monogenic disorders of the beta cell that account for 1–2% of diabetes. They are discrete disorders, which are a significant cause of diabetes in their own right. Correct molecular diagnosis is important to predict clinical course, explain other associated clinical features, enable genetic counseling, diagnose family members, and most importantly guide appropriate treatment. In addition to this clinical importance, the discovery and study of monogenic disorders has given further insight into the physiology and pathophysiology of the beta cell.
MOST POPULAR ARTICLES OF THE MONTH
I received a call and glucose numbers from patient who has type 2 diabetes, usually with hyperglycemia, never hypoglycemia. I noticed there was at least a 12-hour span since the last glucose reading. His glucose levels after the over-12-hour lag showed hypoglycemia during the night when the numbers start showing. His glucose averaged 53 during that time, but it has been running 150 and over, and we have been slowly increasing his insulin.
Free potential treatment lowers blood sugars, helps with weight loss, drops blood pressure and cholesterol, and may add at least 10 years of quality of life.
Medications suggested for second- and third-line treatments for diabetes management following treatment failure with metformin and sulfonylureas.